MRI Lesion Size vs. 76Br-Bromide PET
| Patient | Histology | PET: tumor area (mm2) with increased 76Br-bromide uptake | MRI: tumor lesion size (mm2) | Gadolinium contrast enhancement (T1) | ||
|---|---|---|---|---|---|---|
| T1 area | T2 area | |||||
| 1 | Anaplastic astrocytoma WHO III | 276 | 325 | 1,512 | 1 | |
| 5 | Anaplastic astrocytoma WHO III | 452 | 361 | 2,337 | 1 | |
| 7 | Anaplastic astrocytoma WHO III | 179 | 141 | 448 | 0 | |
| 8 | Anaplastic astrocytoma WHO III | 123 | 577 | 886 | 1 | |
| 9 | Anaplastic astrocytoma WHO III | 653 | 653 | 2,093 | 0 | |
| 2 | Glioblastoma multiforme WHO IV | 1,063 | 934 | 3,413 | 2 | |
| 6 | Meningioma WHO I | 1,081 | 866 | 2,383 | 2 | |
| 4 | Oligoastrocytoma WHO II | 0 | — | 6,858 | — | |
| 3 | Suspected lymphoma | 0 | 974 | 974 | 0 | |
WHO = World Health Organization stage.
Tumor lesion size determined from PET, T1- and T2-MR images, and rankings of gadolinium enhancement in T1-MR images (grade 0 = no enhancement, grade 1 = mild to moderate enhancement, and grade 2 = marked, extensive enhancement). Corresponding MR and PET image planes were used. No gadolinium-enhanced T1-MR images were available in patient 4.